VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 08, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a site consolidation and organizational restructuring to better align its HBV business in Warminster, PA. These organizational changes are expected to result in increased efficiency, a more flexible variable cost structure, and additional preservation of the Companys cash reserves. The Companys Lipid Nanoparticle (LNP) technology group will remain intact.
To achieve this alignment, Arbutus will reduce its global workforce by approximately 31 percent and plans to close its Burnaby facility. The Company will incur rest…
Read the full article at: https://globenewswire.com/news-release/2018/02/08/1336146/0/en/Arbutus-Consolidates-HBV-Business-Around-Warminster-PA-Site.html